Camelot Investigates Trends in the Global Pharmaceutical Industry

22.02.2013 -

The pharmaceutical industry in Europe is facing major changes. The rise of emerging markets and increasing price pressure in established markets are only two of the global challenges confronting pharmaceutical conglomerates. In light of these developments, many companies need to modify their business models. This is why the strategy and organization consultancy Camelot Management Consultants created the PHARMAManagement Radar survey.

"The objective of the regular survey of the industry's global decision makers is to detect changes and management trends and to identify associated opportunities during this exciting phase of change," says Michael Jarosch, Head of Industry Segment Pharmaceuticals & Life Sciences at Camelot Management Consultants. Conducted twice a year, the survey among global industry experts inquires about the most important business climate indicators on the one hand and delves into changing focus topics related to current management trends in the global pharmaceutical industry on the other hand.

"For us as a globally active consultancy firm, it is essential to know how substantially the industry is being changed by what global trends at an early stage, and what challenges our clients are facing as a result," explains Jarosch.

The first PHARMAManagement Radar survey investigates the focus topic "Security of Product Supply" and runs until Monday, March 11, 2013. It is being conducted by means of a specially created website and is intended for all decision makers of global pharmaceutical companies. The survey takes about ten minutes to complete. All panel members will receive the documentation of the results exclusively on the publication date of the PHARMAManagement Radar, either as a PDF or by mail in printed form. The participants' data and information shall be treated as strictly confidential and shall not be forwarded.

The results will be published at the beginning of April in the industry paper CHEManager Europe.